National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine)

Eaststone Limited is initiating a recall of all batches of quetiapine oral suspension products due to a potential risk of overdose, which could have consequences for the safety of patients.

MHRA Drug alert date: 29/01/26

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/national-patient-safety-alert-class-1-medicines-recall-notification-recall-of-quetiapine-oral-suspension-unlicensed-medicine-manufactured-by-eaststone-limited-due-to-a-potential-for-overdosing-natpsa-slash-2026-slash-002-slash-mhr?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=a09ef640-89c2-4758-9ee1-2f562cdba868&utm_content=immediately#download-documents

Eaststone Limited will be contacting customers who have received affected stock directly

Further Information

For more information or stock and, please contact Eaststone Limited on +44(0)800 678 3102 (Select Option 1) or email specials@eaststone.co.uk 

For medical information queries, please contact Eaststone Limited on +44(0)800 678 3102 (Select Option 3) or email umar.ahmed@eaststone.co.uk 

For all other enquires place contact Eaststone Limited +44(0)800 678 3102 (Select Option 3) or email umar.ahmed@eaststone.co.uk 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.